Lv3
390 积分 2022-05-29 加入
Abstract 3495: QL535, A novel CD2-costimulating T cell engager targeting PSMA-positive prostate cancer matching CD28 trispecific antibody in cytotoxicity, minimizing cytokine release and T-cell exhaustion
2天前
求助中
Abstract 2369: EVOLVE-105, a differentiated CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies
2天前
求助中
LB0007 CC312, A NOVEL ENGINEERED CD19/CD3/CD28 TRI-SPECIFIC ANTIBODY，LEADS TO RAPID AND DEEP B-CELL DEPLETION AND HAS BROAD POTENTIAL FOR DEVELOPMENT IN AUTOIMMUNE DISEASES
2天前
已完结
Abstract 2650: Pre-clinical efficacy and toxicity profile of LM-24C5: A novel CEACAM5 x 4-1BB bispecific antibody in cancer immunotherapy
8天前
已关闭
Exploring the next generation of antibody–drug conjugates
28天前
已完结
Deep generative models design mRNA sequences with enhanced translational capacity and stability
1个月前
已完结
Development of a high-throughput solubility screening assay for use in antibody discovery
1个月前
已完结
Strategies for the Generation of Bispecific Antibodies
1个月前
已完结
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement
1个月前
已完结
New insights into antibody structure with implications for specificity, variable region restriction and isotype choice
2个月前
已完结
皖公网安备34019202002308
